List of insiders holdings for Terns Pharmaceuticals Inc.:
- Shares directly owned by the insider.
- Shares indirectly owned by the insider.
- Total shares owned by the insider (sum of shares directly and indirectly owned).
- Total market value if available.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Insider Holder Name | Report Date Time | Shares Owned Directly Indirectly | Total Shares Owned | Filing |
| ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Asia GP III L.P. OrbiMed Advisors III Ltd OrbiMed Genesis GP LLC Director 10% Owner | 2024-09-16 20:29:21 | 7,562,971 0 | 7,562,971 | Form 13D |
| Vivo Opportunity LLC Vivo Opportunity Fund Holdings L.P. Vivo Capital VIII LLC Vivo Capital Fund VIII L.P. Vivo Capital Surplus Fund VIII L.P. 10% Owner | 2024-11-14 19:00:26 | 4,597,243 0 | 4,597,243 | Form 13G |
| Vivo Capital VIII LLC Vivo Capital Fund VIII L.P. Vivo Capital Surplus Fund VIII L.P. Vivo Opportunity LLC Vivo Opportunity Fund L.P. 10% Owner | 2023-02-13 17:57:55 | 4,340,212 0 | 4,340,212 | Form 13G |
| LAV Biosciences Fund V L.P. Hopewell Resources Holdings Ltd LAV Aqua Ltd Oriental Spring Venture Ltd 10% Owner | 2024-02-13 17:21:57 | 2,901,566 0 | 2,901,566 | Form 13G |
| Burroughs Amy L. Chief Executive Officer | 2024-03-05 18:01:54 | 1,400,000 0 | 1,400,000 | Form 4 |
| GORDON CARL L Director 10% Owner | 2024-07-17 20:53:02 | 0 755,635 | 755,635 | Form 4 |
| Zhong Weidong Chief Scientific Officer | 2021-02-04 17:12:41 | 513,520 0 | 513,520 | Form 3 |
| Lu Hongbo Director | 2024-09-17 19:48:06 | 0 476,190 | 476,190 | Form 4 |
| Jung Melita Sun Chief Business Officer | 2024-05-02 17:29:09 | 475,000 0 | 475,000 | Form 4 |
| Kuriakose Emil Chief Medical Officer | 2024-03-19 19:26:45 | 456,250 0 | 456,250 | Form 3 |
| Russell Kerry Strong Chief Medical Officer | 2022-07-06 20:07:09 | 240,000 0 | 240,000 | Form 4 |
| Quirk Erin President, Head of R&D | 2024-01-25 19:17:02 | 225,000 0 | 225,000 | Form 4 |
| Vignola Mark J. Chief Financial Officer | 2024-09-12 18:10:08 | 146,940 0 | 146,940 | Form 4 |
| Yoon Seokho Bryan COO and General Counsel | 2024-06-04 18:06:20 | 91,940 0 | 91,940 | Form 4 |
| Turner Heather D Director | 2024-11-19 18:30:18 | 64,000 0 | 64,000 | Form 4 |
| Quigley Jill M. Director | 2024-09-11 18:00:22 | 15,000 0 | 15,000 | Form 4 |
| Sundaram Senthil Vel Chief Executive Officer | 2023-06-02 17:03:03 | 9,770 0 | 9,770 | Form 4 |
| FELLOWS DAVID A Director | 2024-07-02 18:36:12 | 8,183 0 | 8,183 | Form 4 |
| Taylor Ann Elizabeth Director | 2024-07-02 18:37:36 | 4,676 0 | 4,676 | Form 4 |
| Tripuraneni Radhika Director | 2024-07-02 18:38:01 | 4,676 0 | 4,676 | Form 4 |
| KINDLER JEFFREY B Director | 2024-07-02 18:36:39 | 4,676 0 | 4,676 | Form 4 |
| Flynn James E DEERFIELD MANAGEMENT COMPANY L.P. (SERIES C) DEERFIELD PARTNERS L.P. Deerfield Mgmt L.P. Possible Member of 10% Group 10% Owner | 2023-10-04 17:09:36 | 0 0 | 0 | Form 13G |